Clinical trials: Sitagliptin, completed
Maturity-onset Diabetes of the Young
Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)
The purpose of this study is to describe the incretin effect and postprandial incretin response in patients with MODY2 and MODY3 and a group of matched healthy subjects.
- Trial name
- NCT01342939
- Testing
- Oral Glucose Tolerance Test (OGTT), iso glycaemic intravenous (iv) glucose infusion (IIGI), Meal test
- Where
- Denmark
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Insulin Secretion, Insulin Resistance
Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics
1. The purpose of this study is to determine whether Sitagliptin therapy suppress glucagon release and improve glucose control in Chinese type 2 diabetic. 2.
- Trial name
- NCT01610154
- Testing
- Sitagliptin
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Guangwei Li
Diabetes Mellitus, Type 2
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086502
- Testing
- Comparator: Sitagliptin, Comparator: Pioglitazone, Metformin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
Treatment of Latent Autoimmune Diabetes of the Adult
The purpose of the study is to clarify whether patients classified as Latent autoimmune diabetes of the adult (LADA) benefit from early treatment with insulin added to per oral treatment and lifestyle measures.
- Trial name
- LADA (NCT01140438)
- Testing
- metformin+ NPH insulin, metformin + sitagliptin +/- repaglinide
- Where
- Norway
- Volunteers
- 64 people
- Sponsor
- Norwegian University of Science and Technology
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Japan. The purpose is to compare the safety of once-weekly dosing of semaglutide (0.5 and 1.0 mg) versus sitagliptin (100 mg) once daily, both as monotherapy during 30 weeks of treatment in Japanese…
- Trial name
- SUSTAIN™ (NCT02254291)
- Testing
- semaglutide, sitagliptin
- Where
- 25 sites in Japan
- Volunteers
- 308 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS®) based on a…
- Trial name
- NCT02738879
- Testing
- Sitagliptin, Metformin, Metformin XR
- Volunteers
- 746 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction (HFPEF)
Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- DUP-SUMMIT (NCT06914154)
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 11,265 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00127192
- Testing
- sitagliptin phosphate
- Volunteers
- 363 people
- Sponsor
- Merck Sharp & Dohme LLC
Uncontrolled Type 2 Diabetes Mellitus
Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in…
- Trial name
- NCT04801199
- Testing
- CPL-2009-0031 140 mg, Sitagliptin 100mg
- Where
- 12 sites in India
- Volunteers
- 355 people
- Sponsor
- Cadila Pharnmaceuticals
Diabetes Mellitus, Type 2, Chronic Renal Insufficiency
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function).
- Trial name
- NCT00095056
- Testing
- sitagliptin, glipizide
- Volunteers
- 91 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Liver Transplant; Complications
Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation
Patients with pre-transplantation type 2 diabetes (T2D) and new-onset diabetes post liver transplantation (NODAT) are managed with multiple doses of subcutaneous insulin (MSI) following liver transplantation.
- Trial name
- Dapa-LiT (NCT05042505)
- Testing
- Dapagliflozin 10Mg Tab, Sitagliptin 100mg
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Medanta, The Medicity, India
Type 2 Diabetes
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin…
- Trial name
- NCT00666458
- Testing
- saxagliptin, sitagliptin
- Where
- 87 sites in Argentina, Belgium and 7 more
- Volunteers
- 822 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin…
- Trial name
- NCT01189890
- Testing
- sitagliptin phosphate, Glimepiride
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00642278
- Testing
- Canagliflozin (JNJ-28431754), Sitagliptin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin.
- Trial name
- NCT01098539
- Testing
- albiglutide, sitagliptin
- Where
- 218 sites in United States, Australia and 13 more
- Volunteers
- 507 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00449930
- Testing
- sitagliptin phosphate, Comparator: metformin hydrochloride
- Volunteers
- 1,050 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).
- Trial name
- NCT00103857
- Testing
- Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Comparator: MK0431 100 mg q.d. (q.d. = once daily), Comparator: Metformin 500 mg b.i.d.
- Volunteers
- 1,208 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study Population
This is a phase IV study of 3.5 years duration to evaluate the phenotypic and genetic correlates of diabetes (non-Type 1 in young non-obese Asian Indians in North India and pilot case control study to evaluate the efficacy of…
- Trial name
- NCT00964184
- Testing
- Metformin, Lifestyle modification
- Where
- India
- Volunteers
- 133 people
- Sponsor
- Diabetes Foundation, India
Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation
Primary Objective: It is hypothesized that the efficacy of Sitagliptin would reduce the incidence of grade II-IV acute Graft Versus Host Disease (GVHD) by day +100 post-transplant in patients undergoing alternative donor (related…
- Trial name
- SHIELD (NCT05149365)
- Testing
- Sitagliptin + Standard Prophylaxis, Standard Prophylaxis
- Where
- China
- Volunteers
- 190 people
- Sponsor
- The First Affiliated Hospital of Soochow University